STOCK TITAN

Enlivex (NASDAQ: ENLV) highlights Rain AI launch, $5M grants and RAIN token burn

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
6-K

Rhea-AI Filing Summary

Enlivex Ltd. reported that the Rain Foundation, which oversees the decentralized Rain prediction markets protocol, has launched an AI agent-ready interface and a $5 million grant program. The initiative aims to help developers and creators build, launch, and monetize independent prediction market platforms via AI agents such as OpenClaw.

Enlivex’s CEO highlighted that the company is a major holder of the RAIN token and views Rain’s new single‑prompt market creation as a forward-looking concept. The company believes future revenue growth of the Rain protocol and the appropriation of approximately 2.5% of total trading volume to automatic RAIN token buy-and-burn could benefit RAIN’s value and support Enlivex’s digital asset treasury strategy.

Positive

  • None.

Negative

  • None.

Insights

Enlivex links its biotech story to Rain’s tokenized prediction markets.

Enlivex emphasizes its dual model: developing Allocetra™, an immunotherapy for age-related osteoarthritis, while holding a substantial RAIN token position in a prediction markets treasury. The Rain Foundation’s new AI interface and $5 million grant program are positioned as potential catalysts for protocol activity.

The CEO notes that around 2.5% of total trading volume on Rain is earmarked for automatic RAIN token buy-and-burn. If protocol usage expands, this mechanism could tighten token supply, indirectly affecting the value of Enlivex’s holdings. Actual impact will depend on future trading volumes and broader digital asset conditions.

The filing underscores typical risks around crypto volatility, regulation, and execution of the digital asset strategy, alongside clinical and competitive risks in Enlivex’s longevity programs. Subsequent company reports may clarify how Rain’s growth, or lack thereof, contributes to Enlivex’s financial performance and treasury value over time.

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 6-K

 

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

 

For the month of: March 2026

 

Commission file number: 001-36578

 

ENLIVEX LTD.

(Translation of registrant’s name into English)

 

14 Einstein Street, Nes Ziona, Israel 7403618

(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F         Form 40-F 

 

 

 

 

 

On March 26, 2026, Enlivex Ltd., a company organized under the laws of the State of Israel, issued a press release announcing that the Rain Foundation, which independently oversees the decentralized prediction markets Rain protocol, announced the launch of its AI agent-ready interface and a $5 million grant program to support developers and creators worldwide in building, launching, and monetizing their own independent prediction market platforms through AI agents, including OpenClaw. A copy of the press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference.

 

Exhibit No.  
   
99.1 Press Release

 

 

1

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  Enlivex Ltd.
  (Registrant)
   
  By: /s/ Oren Hershkovitz
 

Name: 

Title:

Oren Hershkovitz
Chief Executive Officer

 

Date: March 26, 2026

 

2

 

Exhibit 99.1

 

Enlivex Rain Update: Rain Launches an OpenClaw and AI Agent Interface Allowing Anyone To Create A Prediction Market Via A Single Prompt

 

·According to the Rain Foundation, anyone using OpenClaw or other AI agents can generate a live prediction market via a single prompt to the agent, without manual coding or centralized gatekeepers
·The Rain Foundation announced a $5 million grant program to support developers and creators worldwide in building, launching, and monetizing their own independent prediction markets via the Rain decentralized platform through AI agents

 

Nes-Ziona, Israel, March 26, 2026 -- Enlivex Ltd. (Nasdaq: ENLV, “Enlivex” or “the Company”), a quality longevity company powered by a prediction markets treasury, today reported that the Rain Foundation, which independently oversees the decentralized prediction markets Rain protocol, announced the launch of its AI agent-ready interface and a $5 million grant program to support developers and creators worldwide in building, launching, and monetizing their own independent prediction market platforms through AI agents, including OpenClaw.

 

With Rain, builders using OpenClaw or other AI agents can take a single prompt and generate a live prediction market without manual coding or centralized gatekeepers. This allows anyone with a particular idea to turn that idea into a functioning market faster than traditional development would allow.

 

As interest in prediction markets continues to grow, the Rain Foundation is opening up the Rain protocol system to a wider group of builders. Developers and AI agents will have access not only to existing markets, but also to the infrastructure needed to create and launch their own applications and prediction markets directly on the protocol.

 

Oren Hershkovitz, CEO of Enlivex, stated, “As a major holder of RAIN in our treasury portfolio, we are pleased with the milestones that the Rain Foundation is accomplishing. Allowing anyone using OpenClaw or other AI agents to generate a live prediction market via a single prompt to the agent is a forward-looking business concept, and we believe this presents the opportunity for the Rain protocol to increase its position as a leading decentralized prediction markets platform. We believe that the expected growth of Rain’s revenues in the next several years would be beneficial to the RAIN token due to the appropriation of approximately 2.5% of the total trading volume to automatic buy-and-burn of the RAIN token.”

 

 

 

 

About Enlivex (Nasdaq: ENLV)

 

Enlivex is a quality longevity Company powered by a prediction markets treasury. The Company is advancing Allocetra™, an advanced clinical-stage immunotherapy targeting inflammatory conditions associated with aging with a primary focus on age-related osteoarthritis.

 

In addition to its clinical programs, Enlivex operates a prediction markets treasury strategy built around the Rain protocol, the leading decentralized prediction markets infrastructure on Arbitrum. This dual strategy combines the development of quality longevity therapeutics with exposure to the emerging prediction markets ecosystem.

 

Forward-Looking Statements

 

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements may be identified by words such as “expects,” “plans,” “projects,” “will,” “may,” “anticipates,” “believes,” “should,” “would,” “could,” “intends,” “estimates,” “suggests,” “target,” “has the potential to,” “goal,” and other words of similar meaning, including statements relating to the anticipated benefits of the Company’s digital asset treasury strategy; the assets to be held by the Company; the expected future market, price, trading activity, and liquidity of the RAIN token; the impact of expanded exchange listings and increased token liquidity on market participation and accessibility; the potential effects of digital asset liquidity on the liquidity of the Company’s ordinary shares; macroeconomic, political, and regulatory conditions surrounding digital assets; the Company’s plans for value creation and strategic positioning; market size and growth opportunities; regulatory conditions; competitive position; technological and market trends; future financial condition and performance; expected clinical trial results; market opportunities for the results of current clinical studies and preclinical experiments; and the effectiveness of, and market opportunities for, ALLOCETRA™ programs.

 

Each forward-looking statement contained in this press release is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement. Applicable risks and uncertainties include, among others, the risk of failure to realize the anticipated benefits of the Company’s digital asset treasury strategy; changes in business, market, financial, political, and regulatory conditions; risks relating to the Company’s operations and business, including the highly volatile nature of the price, trading volume, and liquidity of RAIN and other cryptocurrencies; risks associated with digital asset exchange listings, trading venues, and market infrastructure; the risk that the price and liquidity of the Company’s ordinary shares may be correlated with the price or liquidity of the digital assets it holds; risks related to increased competition in the industries in which the Company operates; risks relating to significant legal, commercial, regulatory, and technical uncertainty regarding digital assets generally; risks relating to the treatment of crypto assets for U.S. and foreign tax purposes; and those risks and uncertainties identified in the Company’s filings with the Securities and Exchange Commission. The forward-looking statements in this press release speak only as of the date of this document, and the Company undertakes no obligation to update or revise any of these statements, except as required by applicable law.

 

ENLIVEX CONTACT

 

Shachar Shlosberger, CFO
Enlivex Ltd.
shachar@enlivex.com 

 

 

 

 

 

 

 

FAQ

What did Enlivex (ENLV) announce about the Rain protocol in this 6-K?

Enlivex reported that the Rain Foundation launched an AI agent-ready interface and a $5 million grant program. This supports developers and creators in building and monetizing decentralized prediction market platforms on the Rain protocol through AI agents, including OpenClaw.

How is Enlivex (ENLV) financially exposed to the Rain protocol and RAIN token?

Enlivex states it is a major holder of the RAIN token within its prediction markets treasury strategy. The company’s potential upside is tied to Rain protocol adoption and to RAIN’s tokenomics, including an automatic buy-and-burn mechanism funded from trading volume.

What is the $5 million Rain Foundation grant program mentioned by Enlivex?

The Rain Foundation launched a $5 million grant program to support developers and creators worldwide. Grants are intended to help them build, launch, and monetize independent prediction market platforms directly on the Rain protocol using AI agents such as OpenClaw.

How does the Rain protocol’s buy-and-burn mechanism work according to Enlivex?

Enlivex notes that approximately 2.5% of total trading volume on the Rain protocol is appropriated to automatically buy and burn RAIN tokens. This structure gradually reduces token supply and could influence RAIN’s value if trading activity increases over time.

What is Enlivex’s core business alongside its digital asset treasury strategy?

Enlivex describes itself as a quality longevity company advancing Allocetra™, a clinical-stage immunotherapy targeting inflammatory conditions of aging, especially age-related osteoarthritis. Alongside these programs, it operates a prediction markets treasury strategy centered on the Rain protocol and RAIN token exposure.

What risks does Enlivex highlight around its digital asset treasury and RAIN holdings?

Enlivex cites risks including high volatility in RAIN and other cryptocurrencies, changing regulatory and tax treatment, and uncertainties around digital asset exchanges and infrastructure. It also notes potential correlation between its share liquidity and the value or liquidity of the digital assets it holds.

Filing Exhibits & Attachments

1 document
Enlivex Ltd

NASDAQ:ENLV

View ENLV Stock Overview

ENLV Rankings

ENLV Latest News

ENLV Latest SEC Filings

ENLV Stock Data

259.67M
236.28M
Biotechnology
Healthcare
Link
Israel
Ness Ziona